Introduction
============

Nonadherence to all treatments is a major problem in the US, where it is estimated to cost \$300 billion in wasted resources[@b1-ppa-11-271] and leads to 125,000 unnecessary deaths[@b2-ppa-11-271] each year. There is a similar and urgent problem among patients with diabetes, which is growing in prevalence and is the seventh leading cause of death.[@b3-ppa-11-271] Patients with diabetes have lower than average adherence,[@b1-ppa-11-271] and poor adherence leads to premature and significant morbidity (blindness, renal failure, congestive heart failure, and amputations). The cost of nonadherence in diabetes alone is in billions annually.[@b4-ppa-11-271],[@b5-ppa-11-271] In the largest study to date, Jha et al[@b5-ppa-11-271] studied 135,600 patients with diabetes and defined adherence as taking their medications 80% of the time. They found that only 60% were adherent, a figure consistent with other studies. They found that nonadherent patients were 15% more likely to be hospitalized and use the emergency room. They calculated that improved adherence to diabetes medication could avert 699,000 emergency department visits and 341,000 hospitalizations annually, for a saving of \$4.7 billion. They also found that 25% of previously adherent patients became nonadherent over the following year. Preventing this loss of adherence would lead to another \$3.6 billion in savings, for a combined potential savings of \$8.3 billion each year. Recognizing this, many strategies and interventions have been used to increase adherence in patients with diabetes, including telemedicine,[@b6-ppa-11-271] automated reminders,[@b7-ppa-11-271] regimen simplification,[@b8-ppa-11-271] regimen tailoring,[@b9-ppa-11-271] electronic monitoring,[@b10-ppa-11-271] motivational interviewing,[@b11-ppa-11-271] diabetes education,[@b12-ppa-11-271] and stratified patient-centered care.[@b13-ppa-11-271]

Clearly, there are many reasons for nonadherence, and there have been many interventions that have targeted each element. However, despite several of these approaches showing effectiveness, in general, glycemic control and overall outcomes remain unsatisfactory.[@b14-ppa-11-271] Therefore, a novel approach has been studied, which is generic and aims to change the way patients think -- and, more importantly, the decisions they make -- about their health care. The technology behind this iOS "app" called PatientPartner is based on science-wide complexity theory,[@b15-ppa-11-271] which has been distilled into an extensively validated, computerized, interactive, immersive experience called Strategic Management Simulation (SMS). The SMS system assesses parameters of thinking (the "how" of thinking that is independent of what one knows) and decision making, which have been shown over the past half century to predict real-world functioning in many fields.[@b16-ppa-11-271]--[@b18-ppa-11-271] SMS assessments have also been able to detect subtle, high-level changes in thinking due to the effects of alcohol, antihistamines, beta blockers, ace inhibitors, tranquilizers, and more.[@b19-ppa-11-271]

SMS has been used in the health care field to assess, recruit, and improve the thinking and decision making of medical students, residents, and nursing students.[@b20-ppa-11-271] Given this track record, it was hypothesized that SMS could be used to improve the thinking and decision making of patients, thereby improving adherence and outcomes. This is the first application of SMS in a patient population.

Methods
=======

This study received approval from the institutional review board at Pinnacle Health, Harrisburg, PA and all subjects provided written consent. Because the intervention was with an iOS-based "app", PatientPartner (PatientPartner is a product of CyberDoctor LLC), which is neither a drug nor a medical device, it did not need to be registered as a clinical trial. A total of 107 subjects, age range from 17 to 71 years (46% male and 54% female), who attended a teaching hospital endocrinology clinic, were referred to the study based on two criteria: their physician judged them to be "severely non-adherent" despite efforts to engage them, and they had elevated glycosylated hemoglobin (HbA1c) \>8.

Subjects were randomly assigned to the intervention or control groups on a 2:1 ratio as they arrived in the clinic.

Intervention group
------------------

At the initial visit, patients in the intervention group played a game "PatientPartner" on an iPad. This 12-min game was played once, and it consisted of an engaging scenario of an easy-to-relate-to person with multiple real-world pressures (job and family) with "good excuses" for their obvious non-adherent health care behavior. Next, the subject immerses herself into this story and deals with these real-world pressures to reflect their typical behavior in their real life. Overall, the game is designed to help patients understand their choices and reach optimal decision points ([Figure 1](#f1-ppa-11-271){ref-type="fig"}).

Subjects then work on a series of brief training vignettes to help them gain mastery over three parameters that are considered to be critical for good decision making in health care: information management, stress coping, and health strategies.

Control group
-------------

At the baseline visit, subjects in the control group agreed to 3 weekly self-reports via telephone; they did not engage with PatientPartner.

Follow-up
---------

At the end of each week for 3 weeks, subjects in both the groups self-rated their adherence to medications, diet, and exercise. This was done over the telephone, and questions were strictly scripted to focus only on these adherence questions: "In the past week, how many days did you take your medicines/follow your diet/exercise?"

Three months after baseline, the HbA1c (done as per usual care in this clinic) was recorded for the intervention group. A decrease in HbA1c 3 months from baseline in this nonadherent group was the primary outcome of this study.

Results
=======

A total of 107 participants were enrolled in the study and randomly assigned to two groups (intervention and control) in a 2:1 ratio. Of the 107 participants, 97 subjects completed the study with a total of 66 in the intervention group and 31 in the control group. An overall multivariate analysis of variance across data points indicated that quality of performance following intervention with PatientPartner exceeded performance in the absence of this intervention (*P*\<0.001). Following this, analysis of variance comparisons were made between the PatientPartner group and controls on percent adherence at baseline and at 3 weeks on self-reports on medication, diet, and exercise. Obtained means and standard deviations as well as *F* values and significance levels for each of these variables are reported in [Table 1](#t1-ppa-11-271){ref-type="table"}. The control group was not different on any of these three measures. The PatientPartner group made significant improvements in adherence on all the three measures ([Figure 2](#f2-ppa-11-271){ref-type="fig"}).

Three months after the PatientPartner intervention, HbA1c had dropped from 10.71 at baseline to 9.62 (*F* ratio 4.14, *P*\<0.05) as shown in [Figure 3](#f3-ppa-11-271){ref-type="fig"}.

Discussion
==========

Diabetes is a rapidly growing condition throughout the world. Although good treatments are available to control it, this goal is defeated by nonadherence to all three pillars of treatment: medication, diet, and exercise. Diabetes medication adherence rates are low compared to even other chronic diseases.[@b1-ppa-11-271] As borne out again by our results, adherence to medication is low, diet is difficult, and exercise is poor. The current study shows that apps such as PatientPartner could play a key role in improving the outcomes as reflected in improved adherence behaviors.

There is a strong evidence that treating type 2 diabetes can decrease morbidity and mortality and provides the basis for renewed attempts in addressing this effectively.[@b23-ppa-11-271] Many creative approaches, for example, disease management and telemedicine, have been shown to be helpful but require ongoing, expensive interventions and are often abandoned. Clearly, new and innovative interventions that are brief require little expertise to administer and are capable of being easily administered to a large number of patients are the need of the hour. In this context, it is impressive that a brief (12 min), one-time noninvasive intervention with Patient-Partner can change outcome behaviors and lead to patients taking their medication more regularly (from \~4 days a week to almost every day), eating a healthier diet (from 3.5 days a week to over 5), and exercising regularly (clearly the most difficult, it went up from 2 days a week to 3). Although this is statistically significant and clinically meaningful, it is short term (just 3 weeks) and is based on self-reports. To remedy this, the primary end point chosen was HbA1c, the objective, biological gold standard for blood glucose that is an average of levels over 3 months. With just one brief intervention, there was a significant and clinically meaningful drop in HbA1c from 10.7 to 9.6. Although 9.6 is still high, a decrease of 1.1 in 3 months in a very nonadherent group is noteworthy.

Today, \>200,000 medical apps are available. Numerous apps can monitor and reward, for example, through "gaming" principles, the progress of a person's diabetes. However, this is the first app that has been proven in a clinical trial to be effective in improving an objective biological marker of diabetes, HbA1c. More importantly, this is a general app that affects the way people think and make decisions (including about their health) but is not in any way geared specifically to diabetes. Therefore, this app has the potential to improve the care and outcome not just in diabetes but in any medical condition.

This is a pilot study with shortcomings. The sample needs to be larger. Given limited resources, our strategy was to recruit chronically poorly controlled patients to see whether we could make an impact in the most difficult population. We do not know the utility of this app in the general population of people with diabetes although it looks promising. Diabetes is a chronic disease, and a 3-month trial is short; we need to study it long term to evaluate for how long this one 12-min intervention can exert a positive influence. When would a booster session be needed?

The app was well tolerated by all ages, including the elderly. All subjects could complete the game, including the many subjects who were disadvantaged (less educated or from lower socioeconomic strata), as is typical of a public clinic.

Medical apps such as PatientPartner can be added to the many approaches that we currently use and have the potential to improve adherence and outcomes and decrease costs for the care of patients with chronic illness (including billions of dollars for diabetes alone). However, apps need to be clinically tested and proven effective before being adopted. There is only one app that is specific to cancer and that has been proven to be helpful.[@b24-ppa-11-271] There is only one effective app, PatientPartner, which is nonspecific to any particular disease because it focuses on three general parameters of thinking and decision making: information management, stress coping, and health strategies. This pilot study shows that patients can be assessed and trained in a very short time. Teaching them skills to solve real-world relevant problems in innovative, sequential, and strategic ways can help improve adherence behaviors. This can therefore be effective in all diseases. More studies are needed to prove PatientPartner's effectiveness in other disease states.

Our review suggests that improved adherence among patients with diabetes (and all chronic diseases) should be a key goal for clinicians, the health care system, and policy makers. Given the less than optimal results from current approaches, new and innovative approaches need to be encouraged, clinically tested, and then implemented.
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###### 

Mean changes in intervention and control group on medication, diet, and exercise at 3 weeks

  Variables                N    Base mean (%)   Final mean (%)   *F* ratio   *P*-value
  ------------------------ ---- --------------- ---------------- ----------- -----------
  **Intervention group**   66                                                
  Medication                    57 (SD 18)      96 (SD 9)        386         0.001
  Diet                          50 (SD 33)      75 (SD 28)       28.7        0.001
  Exercise                      29 (SD 31)      43 (SD 33)       7.6         0.007
  **Control group**        31                                                
  Medication                    58 (SD 20)      68 (SD 45)       1.1         0.30
  Diet                          35 (SD 29)      48 (SD 36)       0.74        0.39
  Exercise                      32 (SD 23)      31 (SD 24)       0.92        0.34

**Abbreviation:** SD, standard deviation.
